Operator
Good morning, and welcome to the Invo Fertility Reports 3rd Quarter Fiscal Year 2026 Financial Results. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may type it into the Ask a Question box on the webcast screen. Please note this event is being recorded. I would now like to turn the conference over to Robert Bloom with Latham Partners. Please go ahead.
All right. Thank you very much, Chloe, and good morning, everyone. Thank you all for joining us to discuss Invo Fertility's third quarter 2026 results. This is for the period ended September 30th, 2026. With us on the call today is Steve Shum, the company's chief executive officer, and Tara Krigsvold, the company's chief financial officer. As the operator indicated at the conclusion of today's prepared remarks, we'll open the call for a question and answer session. If you are listening through the webcast portal and would like to ask a question, you can submit it through the Ask a Question feature in the webcast player. Before we begin, we submit for the record the following statement. Statements made by the management team of InvoFertility during the course of this conference call may contain forward-looking statements within the meaning of the federal securities laws. These statements describe future expectations, plans, results, or strategies, and are generally identified by words such as may, will, should, expect, anticipate, believe, estimate, intend, plan, or similar expressions. Listeners are cautioned that such statements are subject to risks and uncertainties that could cause actual circumstances, events, or results to differ materially from those projected, including the risks described in the company's filings with the Securities and Exchange Commission. All forward-looking statements speak only as the date they are made, and the company undertakes no obligation to update them except as required by law. Today's discussion will also include adjusted EBITDA and clinic-level adjusted EBITDA, which are non-GAAP financial measures. Reconciliations and additional information regarding these measures are included in today's press release. With that said, I'd like to turn the call over to Steve Shum, Chief Executive Officer of InvoFertility. Steve, please proceed.
Thank you, Robert, and good morning. We appreciate everyone joining us on the call today. We are excited to review our third quarter and year-to-date results today, which reflect the further progress toward building and growing our clinic platform, as well as strengthening our operational capabilities and balance sheet, which we believe has greatly improved the value of the company and sets an attractive stage for continuing to drive performance and value in the business moving forward. I also want to thank both our corporate team and each of our clinical teams. Their efforts and hard work are truly making this progress possible. We are equally excited about the recent progress as it relates to us being a public company. Private equity has historically played a leading role in bringing fertility practices together, building successful network groups, and helping clinics serve more patients. But in that setting, only select investors have the opportunity to benefit from the overall growth in fertility care and the efficiencies created from larger networks. Also, independent clinic operators interested in becoming part of a larger network have mostly only had the private markets as a potential exit. So, as a publicly traded clinic operator, INVO gives public investors a way to participate in that opportunity, and we can also provide independent clinic operators an alternative pathway, and one that has, in our opinion, some added benefits due to our public status. We certainly have much more work to do, but again, we've made excellent progress this year and see some very exciting opportunities to extend and even accelerate this progress as we move forward. The gains being made here were clearly reflected in this quarter's results. Clinic revenue reached a record of 28% year-over-year, and our clinics generated positive clinic-level adjusted EBITDA for the seventh consecutive quarter, even as we made planned investments to support the transition at our Birmingham clinic. Credit goes to our local clinic teams and the corporate operations team. We will also look to continue to take what's working in our clinics today and use it to help further expand our clinic base. Ultimately, our goal is to expand access to fertility care for patients, grow our clinic network both organically in the existing clinics we operate, as well as increase the total number of clinics, all of which should drive substantial shareholder value from current levels. We fundamentally believe this is achievable. By bringing human resources, billing, finance, and administrative support across together across the network, we will also look to operate more efficiently and get physicians and their teams more time to focus on patients. One of the things we hear from physicians is how much of their day can be taken up by the administrative work. For a local practice, the billing, documentation, and administrative demands are real, regardless of how many patients come through the door. Our approach and platform aims to take on much of that work while keeping patient care in the hands of the people who know the patient best. Wisconsin is a good example of these efforts. Earlier this year, Wisconsin Fertility Institute joined the Progeny Network. That gave people with progeny benefits a way to use their coverage at our practice. We believe that broader access is helping Wisconsin to grow. Atlanta also contributed to organic growth in the period as we implemented several efforts to help expand that practice. We are also evaluating and, in some cases, already implementing additional tools to help further improve efficiencies across the practices. As we noted in the press release, our Birmingham clinic was in a transition mode during the period. When we agreed to acquire the remaining half of the practice in June of this year, we knew we would need to go through a transition and incur some added costs after closing. The purchase terms reflected that as we paid a nominal amount along with certain deferred considerations. Bringing in a new physician and adding services were part of that plan for the clinic under our full ownership. We anticipated a near-term effect on earnings. As the team worked through that transition, revenue was lower and costs were higher during the quarter for the Birmingham clinic. The transition affected our reported clinic results, and the reconciliation separately identifies approximately $193,000 of Birmingham restructuring impact excluded from our clinic-level adjusted EMODOC. It's important to note that each practice has its own unique needs to help grow and drive success. As we continue to expand and seek out additional acquisitions, that's what we want physicians to see in Invo, a partner that understands their practice and focuses on what is needed most. We feel that idea resonated in our conversations at ASRM, the industry's largest assisted reproductive conference recently held this year in Baltimore. We heard encouraging feedback on both growing practices we already operate and bringing established practices into our network. For a physician considering a partner, it matters that we can talk from experience about what changes when a clinic joins INVO and how we support its team. As we evaluate acquisitions, we are looking for established, profitable practice with experienced clinical teams. We want to understand the practice, what the physicians want for its future, and where our support can make a difference. We also look closely at the investment a clinic will need after closing. All of that drives how we structure a potential deal. The financial objective is straightforward. As our clinics grow and we add practices, we want to combine clinic earnings to cover an increasing share of our corporate costs of running INBO as we work toward overall consolidated profitability. Seven quarters of positive clinic-level adjusted EBDOD give us that solid base to build on. Reaching sustained profitability for the company as a whole is the work ahead, and we believe we can get there. To support the next stage of our growth, it was imperative that we improve the balance sheet. Last year, we spent some time walking through the transformation that we have undertaken to clean up the balance sheet. But let me highlight just a few key takeaways we have made since the end of December 2025. First, we reduced our outstanding acquisition payment obligations from $4.2 million to approximately $1 million. This primarily represented the paydown of what we owed on the previous Wisconsin acquisition. Second, current liabilities fell from $10.3 million to $4.5 million. That's a reduction of $5.8 million in nine months. Third, cash increased from $2.1 million to $3.7 million. As of September 30th, we have approximately $3.10 per share in cash, more than the value of our shares today. Fourth, our working capital deficit narrowed from $7.6 million to essentially zero. And fifth, stockholders' equity increased from $7.2 million to $18 million over those same nine months, which equates to about $15 per share as of September 30th. We will continue to manage cash carefully and grow the earnings of our clinics, but with substantially fewer obligations coming due and a stronger capital base, we believe we're better positioned today than at any point in our recent history to execute on the business plan we have set forth. With that, I'll turn the call over to Tara for the financial review, and then I'll come back with a few closing thoughts. Tara?
Thank you, Steve, and good morning, everyone. I'll focus on revenue, the earnings contribution from our clinics, and the change in our balance sheet. The financial tables in our earnings release provide the additional detail. Revenue was $2.2 million, up 26% from $1.8 million a year ago. Clinic revenue rose 28% to $2.2 million. The increase reflected growth in Wisconsin and Atlanta, the contribution from Indiana, and the inclusion of Birmingham following the June acquisition. Cost of services was approximately $1.4 million. Selling, general, and administrative expenses were approximately $2.1 million compared with $2.1 million a year ago. Our operating loss was approximately $1.5 million compared with $1.6 million a year ago, and net loss narrowed to $2.1 million from $3.4 million. A significant part of that improvement relates to a $1.4 million debt extinguishment loss in last year's quarter. Clinic-level adjusted EBITDA was approximately $292,000 compared with $243,000 a year ago. The current quarter adjusted figure excludes the Birmingham impact. As Steve mentioned, the planned transition in Birmingham had an estimated 193,000 impact in the quarter, reflecting lower revenue and higher costs as the new physician came on board and the clinic added certain services. Consolidated adjusted EBITDA was a loss of approximately $962,000 compared with a loss of approximately $948,000 a year ago. That measure includes corporate and public company costs we incur to support the business. The clinic level measure shows the contribution of the practices before those expenses. Turning to the balance sheet, we made a $1.3 million payment toward the acquisition of Wisconsin Fertility Institute during the quarter. That payment contributed to the reduction in current liabilities, which were $4.5 million at September 30th, down from $10.3 million at year-end. We ended September with $3.7 million in cash, compared with $2.1 million at the end of last year. Reducing those obligations is an important step. We continue to manage liquidity carefully as we invest in the practices and work toward generating enough cash from consolidated operations to fund the business. As of November 16, 2026, we had 1,192,860 shares of common stock outstanding. With that financial overview, I'll turn the call back to Steve.
Great. Thank you, Tara. When we think about the next stage for INVO, we see opportunities both inside our four clinics and in the broader market. It goes without saying our team is very excited. In our existing practices, the priorities are to reach more patients, make care easier to access, and support our local clinical teams so they can deliver outstanding care to patients. The experience we gain doing that also makes us a more informed partner for future positions considering and joining our platform. Our balance sheet is stronger than it has been in many years. We have a platform that continues to contribute positive clinic-level earnings, and we have a clear view of the kinds of practices we want to add. Equally important, our pipeline of potential acquisition remains robust and expanding. That combination is what makes us excited about the future. I also want to quickly address our valuation, which, in my opinion, is very attractive. As we see here today, we have a market cap of just under $3 million for a business that has an approximate $9 million annualized revenue run rate based on third quarter results, positive clinic-level cash flows, and a significantly improved balance sheet. Since the start of this year, we've added family beginnings in Indiana, taken full ownership of Birmingham, and expanded access for patients in Wisconsin through Progeny. We have a solid fundamental foundation and value proposition that we look forward to building upon. We have assembled an excellent team that we believe are capable of driving our mission and success and create increased value within the organization. I want to thank our physicians, lab staff, clinical staff, and administrative teams. The trust patients place in their local care teams is at the heart of what we are building. Thank you as well to our shareholders for your continued support. Robert, I think we're ready to open up for any potential questions.
Thank you very much, Steve and Tara, for the prepared remarks. I want to open up the webcast portal here for any questions that there might be from the audience. Again, if you'd like to ask a question, you can type it into the Ask a Question feature on the webcast player. We'll pause for just a moment to see if there are any questions. All right, Steve, showing no questions here, I will turn it back over to you for closing remarks.
Okay, great. Well, we do recognize that we notified everybody of our earnings call a little late, so we want to thank those that did join us today, but if you do have follow-up questions, please do not hesitate to reach out to us anytime. We look forward to updating everyone on our progress next quarter, and have a great day.
Operator
The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.